FindTrial
Sign In

Comparison of two different treatment regimens for treatment of leprosy.

Efficacy of Combination of Rifampicin, clarithromycin, ofloxacin and minocycline versus Multibacillary Multi Drug Therapy Drugs in leprosy and the changes seen on Dermoscopy and histopathology - A Randomized Control Trial Study.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/08/045078
Enrollment
40
Registered
2022-08-30
Start date
Unknown
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: A304- Borderline lepromatous leprosy Health Condition 2: A303- Borderline leprosy Health Condition 3: A302- Borderline tuberculoid leprosy Health Condition 4: A300- Indeterminate leprosy Health Condition 5: A305- Lepromatous leprosy Health Condition 6: A309- Leprosy, unspecified Health Condition 7: A308- Other forms of leprosy Health Condition 8: A301- Tuberculoid leprosy

Interventions

Intervention1: R-COM THERAPY: Rifampicin 600mg once a month for 12 months Clarithromycin 1000mg once a month for 12 months Ofloxacin 400mg daily for 12 months Minocycline 100mg daily for 12 months Con

Sponsors

S Nijalingappa Medical College and HSK Hospital and Research centre
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients of both genders who are newly diagnosed with leprosy and are willing for study

Exclusion criteria

Exclusion criteria: Patient below 5 years and above 90 years. Patient refusal to give consent Pregnant and lactating females.

Design outcomes

Primary

MeasureTime frame
Changes in clinical features, Dermoscopy changes would be checkedTimepoint: Every 4 weeks—

Secondary

MeasureTime frame
Changes in Histopathology would be checked.Timepoint: every 24 weeks—

Countries

India

Contacts

Public ContactDr Sourab D

S. Nijalingappa Medical College and HSK Hospital and Research centre

drbsankad@gmail.com9980410056

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026